BIIB — BIOGEN INC.
—
Nasdaq ·
Health Care ·
Biotechnology ·
CIK 875045 ·
Last close
$250.79
Market Cap
$37.07B
52W High
$261.00
52W Low
$160.36
ADV30
1,244,142
Next earnings
2026-10-28
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Sep 2026 | — | — | — | — | — | — | — |
| Jun 2026 | 2,736,000,000 | 1,959,100,000 | 482,800,000 | 97,500,000 | 32,086,600,000 | 1,285,000,000 | 13,238,600,000 |
| Mar 2026 | 2,477,800,000 | 1,816,800,000 | 459,800,000 | 319,500,000 | 29,483,100,000 | 3,382,700,000 | 10,831,400,000 |
| Dec 2025 | 2,279,400,000 | 1,783,900,000 | 385,500,000 | -48,900,000 | 29,439,500,000 | 3,008,500,000 | 11,182,700,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$2,878,800,000
Investing CF
$-5,315,500,000
Financing CF
$985,000,000
CapEx
$-388,800,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$2.34
As of
2026-11-01
Balance + Analyst (yfinance extras)
Retained Earnings
$20,969,700,000
Inventory
$2,384,300,000
Receivables
$2,398,400,000
ST Investments
$0
EBIT TTM
$1,296,200,000
Pretax Income TTM
$1,011,400,000
Interest Exp TTM
$284,800,000
Analysts
32
Yahoo Snapshot (yfinance, live)
Total Revenue
$10,297,299,968
EBITDA
$3,302,099,968
Free Cash Flow
$808,124,992
Enterprise Value
$43,987,566,592
Total Cash
$1,303,900,032
Total Debt
$7,801,299,968
Shares Out
147,820,223
Trailing EPS
$2.31
Book Value
$128.01
ROE
1.9%
ROA
4.9%
Div Yield
0.00%
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 9,890,600,000 | 2,469,000,000 | 1,292,900,000 | 29,439,500,000 | 11,182,700,000 | 18,256,800,000 | 2,204,600,000 |
| Dec 2024 | 9,675,900,000 | 2,280,400,000 | 1,632,200,000 | 28,049,300,000 | 11,333,300,000 | 16,716,000,000 | 2,875,500,000 |
| Dec 2023 | 9,835,600,000 | 1,847,700,000 | 1,161,100,000 | 26,844,800,000 | 12,045,400,000 | 14,799,400,000 | 1,547,200,000 |
| Dec 2022 | 10,173,400,000 | 2,901,900,000 | 3,046,900,000 | 24,554,100,000 | 11,165,700,000 | 13,397,900,000 | 1,384,300,000 |
TTM Snapshot
Revenues TTM
$10,027,900,000
NetIncome TTM
$834,600,000
OpCashFlow TTM
—
Assets (Latest)
$32,086,600,000
Forward EPS
$16.27
Max Pain — expiry 2027-06-17 (volume-derived — Yahoo OI feed degraded)
max pain strike: $260.00 · spot: $251.41 · call volume: 125 · put volume: 1,081
Expected Move to 2027-06-17:
±$64.77
(25.76%) —
implied range
$186.64 –
$316.18
· ATM straddle on $250.00 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| RVMD | Revolution Medicines, Inc. | $35.19B | $162.69 | — |
| ARGX | ARGENX SE | $58.92B | $947.52 | — |
| BNTX | BioNTech SE | $21.32B | $84.86 | — |
| NBIX | NEUROCRINE BIOSCIENCES INC | $16.79B | $165.92 | — |
| EXEL | EXELIXIS, INC. | $16.71B | $68.50 | — |
News headlines (Yahoo Finance, 1h cache)
Biogen reports two-year Phase II data for diranersen in Alzheimer’s
2026-11-19 09:59 · Yahoo
What Could Biogen (BIIB) Gain From Its New Protein Degrader Research Deal?
2026-11-19 03:29 · Yahoo
New Three-Year Real-World LEQEMBI® Data Presented at CTAD 2026
2026-11-18 16:00 · Yahoo
Biogen (BIIB) Posts Positive Two Year Diranersen Results And Five Year Lecanemab Data
2026-11-18 15:16 · Yahoo
Biogen (BIIB) Stock May Be 49% Undervalued After Fresh Alzheimer’s Data
2026-11-18 14:14 · Yahoo
Biogen (BIIB) After Fresh Alzheimer’s Data, Is The Valuation Story Still Compelling?
2026-11-18 13:11 · Yahoo
Biogen Prepares Joint Lupus Trial Results as It Targets First Revenue Growth Since 2019
2026-11-17 23:12 · Yahoo
Biogen: 3 Key Takeaways for Long-Term Investors
2026-11-17 22:05 · Yahoo
Diranersen demonstrates increasing clinical benefit at two years in early Alzheimer’s disease
2026-11-17 21:45 · Yahoo
New Five-Year Lecanemab Data from Clarity AD Study Long-Term Extension Presented at CTAD 2026
2026-11-16 23:00 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.